Treating gene therapy as an approved platform could lower costs

Transcript

Transcribed by machine (Whisper) from the episode’s audio, so a word may be off here and there.

1. 53:57

   How would you actually cure the top 5,000 diseases? What came back is a thought experiment, not a result. And it's addressed to you, Peter. I've asked Steve's avatar to walk you through it. Start with arithmetic. A new drug costs about $2 billion to bring to approval. 5,000 of them is $10 trillion. That is every pharmaceutical research dollar on Earth for more than 30 years. That's not a funding problem.

2. 54:26

   It's proof the method is wrong. So, change one thing. Stop approving a drug. Approve a process. The gene editor, the particle that delivers it, the manufacturing line, the safety protocol. Approved once. After that, a new disease is a change of sequence inside a process that is already approved. If that takes the cost of adding a disease from $2 billion to $2 million, 5,000 diseases cost $10 billion, less than two weeks of what the industry spends on research.

3. 54:59

   The whole idea is that at one factor of a thousand. And it has already happened, twice, by hand. In 2018, doctors in Boston designed a drug for one girl's unique mutation and gave it to her within a year. In 2025, a team in Philadelphia wrote a gene editing therapy for one baby's single-letter typo, about six months from diagnosis to first dose. These were proofs of speed, not cures. But in both, the platform already existed, and the child's own sequence was compiled into it.

4. 55:34

   They stayed heroic one-offs because the system treats every compile as a new invention. So what stands in the way? Not what you'd guess. Gate 1 is delivery, getting the therapy into the right tissue. By this note's reckoning, that works today for the liver, the blood, and the eye. It does not work for the kidney or for most of the brain. Gate two is diagnosis, before the damage is permanent. About half of patients with a rare genetic disease never get a molecular diagnosis, and the rest wait about five years.

5. 56:09

   Gate three is the cost of a batch of one. Then regulation, then who pays. Notice what is not first. AI solving biology. Perfect knowledge of a disease you cannot reach is not a cure. So, Peter, three asks. One, a prize shaped like gate one. Safe, repeatable delivery of a gene editor to a tissue that cannot be reliably reached today. Kidney, or heart. Objective, measurable, unsolved. And it unlocks thousands of diseases, not one.

6. 56:44

   Two, the damage clock. For each disease, the latest moment a correction still restores function. As far as this note can tell, nobody has assembled it. Three, the regulatory lever. Since 2022, American law has let evidence about a shared platform carry from one approved product to the next. It is new. Making it truly transfer will be won by convening, not by research. And one thing back. The scarcest resource for these patients isn't money.

7. 57:15

   It's expert attention. America has about 1,200 certified medical geneticists for 25 to 30 million people with a rare disease. You can't train your way out of that this decade. You might compute your way out. Whether a machine... A machine can do a geneticist's workup is not known. It can be measured, cheaply, on cases that are already solved. That is the experiment to run first. It's also where our work touches yours.

8. 57:42

   Lightwave is designing a machine that gives one conversation a million tokens a second. It is a design, nothing is built. This is a thought experiment, so here is what would kill it. If delivery to one tissue teaches you nothing about the next, the ceiling is hundreds of diseases, not thousands. If regulators want a full package for every disease, the factor of a thousand disappears. If a dose still costs millions, nobody can pay.

9. 58:11

   Each of those can be checked, cheapest first. 5,000 diseases, not 5,000 discoveries, a handful of processes compiled 5,000 times. What's missing is the address and the permission. One is shaped like a prize. The other needs a convener. That is why this is addressed to you.